Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 95 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ February 7, 2019 The RAD51-IF Test Is Feasible for Assessment of the Functional Status... May 7, 2021 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Load more HOT NEWS First-Line Encorafenib, Binimetinib, and Cetuximab Combination Provides Clinical Benefit and Manageable... Woman Helps Students With Special Needs Achieve Success After Graduation A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... Opinion: ‘The idea that a tobacco company might profit off my...
